Why the study?
Cutaneous angiosarcoma is a rare, locally aggressive malignancy requiring individualized treatment due to a paucity of randomized trials.
In cutaneous angiosarcoma, paraneoplastic neurological syndromes like opsoclonus myoclonus syndrome may herald recurrence, and aggressive multimodality treatment can prolong survival.
May support paclitaxel-pazopanib in cutaneous angiosarcoma with OMS; hypothesis-generating, prospective trials needed.
Cutaneous angiosarcoma is a type of rare and locally aggressive malignancy requiring individualised treatment owing to paucity of randomised trials. We present the case of a middle-aged cancer survivor with locally advanced angiosarcoma of scalp managed with surgery, radiotherapy, chemotherapy and targeted therapy over a course of 6 years for two recurrences. The first recurrence was preceded by opsoclonus myoclonus syndrome, a type of paraneoplastic neurological syndrome (PNS), rarely reported in sarcomas. The second recurrence had a rapid clinical course, which led to a therapeutic dilemma of best supportive care versus active management. A trial of weekly paclitaxel was started that was continued for a total of 12 cycles with good objective clinical response. Presently, he is tolerating maintenance pazopanib well and is symptom free for 6 months. In cutaneous angiosarcoma patients, PNS may be a harbinger of recurrence and aggressive, multimodality treatment helps prolong survival.
No takes yet. Share an insight, caveat, or question.
Periasamy et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: